Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more
Travere Therapeutics Inc (TVTX) - Total Assets
Latest total assets as of December 2025: $605.19 Million USD
Based on the latest financial reports, Travere Therapeutics Inc (TVTX) holds total assets worth $605.19 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Travere Therapeutics Inc - Total Assets Trend (2010–2025)
This chart illustrates how Travere Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Travere Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Travere Therapeutics Inc's total assets of $605.19 Million consist of 72.3% current assets and 27.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.4% |
| Accounts Receivable | $80.13 Million | 13.2% |
| Inventory | $5.88 Million | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $113.87 Million | 18.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Travere Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Travere Therapeutics Inc's current assets represent 72.3% of total assets in 2025, a decrease from 100.0% in 2010.
- Cash Position: Cash and equivalents constituted 15.4% of total assets in 2025, down from 100.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 18.8% of total assets.
Travere Therapeutics Inc Competitors by Total Assets
Key competitors of Travere Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Travere Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Travere Therapeutics Inc generates 0.81x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Travere Therapeutics Inc is currently not profitable relative to its asset base.
Travere Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.74 | 2.08 | 6.65 |
| Quick Ratio | 2.70 | 2.04 | 6.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $277.66 Million | $ 215.95 Million | $ 480.03 Million |
Travere Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Travere Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.87 |
| Latest Market Cap to Assets Ratio | 4.18 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | $605.19 Million |
| Market Capitalization | $2.53 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Travere Therapeutics Inc's assets at a significant premium ( 4.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Travere Therapeutics Inc's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Travere Therapeutics Inc (2010–2025)
The table below shows the annual total assets of Travere Therapeutics Inc from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $605.19 Million | +1.86% |
| 2024-12-31 | $594.12 Million | -24.69% |
| 2023-12-31 | $788.91 Million | +17.30% |
| 2022-12-31 | $672.59 Million | -13.40% |
| 2021-12-31 | $776.63 Million | +27.85% |
| 2020-12-31 | $607.44 Million | +0.44% |
| 2019-12-31 | $604.80 Million | -14.72% |
| 2018-12-31 | $709.16 Million | +36.29% |
| 2017-12-31 | $520.35 Million | -0.94% |
| 2016-12-31 | $525.28 Million | +2.51% |
| 2015-12-31 | $512.40 Million | +278.24% |
| 2014-12-31 | $135.47 Million | +560.87% |
| 2013-12-31 | $20.50 Million | +757.24% |
| 2012-12-31 | $2.39 Million | +61073.32% |
| 2011-12-31 | $3.91K | -1.24% |
| 2010-12-31 | $3.96K | -- |